Re: The Clinton Foundation encouraged foreign companies to ignore (and break) US patent and intellectual property laws.

2016-09-22 Thread Navybrat
Corruption at it's worse. I don't think I could hate this woman more

On Tuesday, September 20, 2016 at 8:19:01 PM UTC-6, Perplexed wrote:
>
>
> And even the New York Times admitted it. I came across this in researching 
> the recent allegations that the Clinton Foundation used an Indian drug 
> manufacturer that is prohibited from selling drugs in the US due to its 
> known horrific lack of quality. This was from 2007:
>
> Clinton Foundation Announces a Bargain* on Generic AIDS Drugs 
>
> By CELIA W. DUGGER MAY 9, 2007 
>
> Former President Bill Clinton announced yesterday that his foundation had 
> negotiated deep price reductions for generic versions of costly, 
> second-line AIDS 
> 
>  
> drugs needed when the original medicines fail, as well as for less toxic, 
> easier-to-use first-line medicines combined in a pill that can be taken 
> once a day.
>
>
> Standing next to Thailand 
> ’s
>  
> health minister, Mr. Clinton also forcefully endorsed recent decisions by 
> Thailand and Brazil 
> 
>  
> to break patents held by American pharmaceutical companies that are 
> charging prices Mr. Clinton described as exorbitant, but that drug company 
> officials said were reasonable.
>
> “No company will live or die because of high price premiums for AIDS drugs 
> in middle-income countries, but patients may,” he said.
>
>
> The new prices would halve the cost of the drugs for better-off developing 
> countries in Latin America and Asia and cut prices by 25 percent in poor 
> countries, which were already paying lower prices, the foundation said. The 
> second-line medicines will be bought with more than $100 million raised by 
> a group of countries led by France. The improved first-line therapies will 
> largely be financed by the Global Fund to Fight AIDS, Tuberculosis and 
> Malaria and other donors.
>
>
> Second-line drugs have typically cost about 10 times as much as first-line 
> therapies. Costs have ballooned in Brazil and Thailand, which began 
> programs to provide universal access to AIDS treatment years before African 
> countries did, as patients have developed resistance to generic first-line 
> treatments and have moved to brand-name second-line drugs.
>
>
> The Clinton Foundation’s willingness to buy the generic drugs from the 
> Indian manufacturers Cipla and Matrix will give developing countries 
> leverage in bargaining with American companies for lower prices on branded 
> antiretroviral drugs and may embolden some to follow Brazil and Thailand in 
> overriding patents, AIDS activists said.
>
>
> But developing countries still have reason to worry about retaliation from 
> drug companies and trade sanctions by the United States. This year, Abbott 
> Laboratories, based in Illinois, withdrew new drugs, including those for 
> high blood pressure 
> 
>  
> and AIDS, that it had planned to introduce in Thailand until the override 
> on Abbott’s patent on the second-line drug, Kaletra.
>
>
> United States trade officials last week put Thailand on a watch list for 
> countries inadequately safeguarding the intellectual property rights of 
> American companies, noting the overriding of drug patents.
>
>
> Tido von Shoen-Angerer, who leads the campaign by Doctors Without Borders 
> for access to medicines, said he was unsure whether the recent developments 
> would encourage developing countries to exercise their rights under 
> international trade rules more freely to make or import generic drugs.
>
> “There’s a strong chilling effect from the U.S. action,” he said.
>
>
> Drug company officials yesterday strongly defended their policies of 
> charging better-off developing countries more for AIDS drugs than they did 
> for poor countries, as well as the role of patents, which give inventor 
> companies a monopoly on the sale of a drug, in stimulating the development 
> of new drugs.
>
>
> Jennifer Smoter, a spokeswoman for Abbott, said patents were needed “to 
> ensure innovation in the future” but declined to respond to Mr. Clinton’s 
> comment that “Abbott has been almost alone in its hard-line position here 
> over what I consider to be a life and death matter.”
>
>
> Abbott had been charging $2,200 annually per patient for Kaletra in 
> middle-income developing countries, which include India, China, Brazil and 
> Ukraine. Last month, it dropped the price to $1,000. The foundation’s new 
> price for the generic is $695.
>
>
> Jeffrey L. Sturchio, a vice president at Merck 
> 

Fwd: [grendelreport] The Clinton Foundation encouraged foreign companies to ignore (and break) US patent and intellectual property laws.

2016-09-22 Thread Travis
And even the New York Times admitted it. I came across this in researching
the recent allegations that the Clinton Foundation used an Indian drug
manufacturer that is prohibited from selling drugs in the US due to its
known horrific lack of quality. This was from 2007:
Clinton Foundation Announces a Bargain* on Generic AIDS Drugs



By CELIA W. DUGGER MAY 9, 2007



Former President Bill Clinton announced yesterday that his foundation had
negotiated deep price reductions for generic versions of costly,
second-line AIDS

drugs needed when the original medicines fail, as well as for less toxic,
easier-to-use first-line medicines combined in a pill that can be taken
once a day.



Standing next to Thailand
’s
health minister, Mr. Clinton also forcefully endorsed recent decisions by
Thailand and Brazil

to break patents held by American pharmaceutical companies that are
charging prices Mr. Clinton described as exorbitant, but that drug company
officials said were reasonable.

“No company will live or die because of high price premiums for AIDS drugs
in middle-income countries, but patients may,” he said.



The new prices would halve the cost of the drugs for better-off developing
countries in Latin America and Asia and cut prices by 25 percent in poor
countries, which were already paying lower prices, the foundation said. The
second-line medicines will be bought with more than $100 million raised by
a group of countries led by France. The improved first-line therapies will
largely be financed by the Global Fund to Fight AIDS, Tuberculosis and
Malaria and other donors.



Second-line drugs have typically cost about 10 times as much as first-line
therapies. Costs have ballooned in Brazil and Thailand, which began
programs to provide universal access to AIDS treatment years before African
countries did, as patients have developed resistance to generic first-line
treatments and have moved to brand-name second-line drugs.



The Clinton Foundation’s willingness to buy the generic drugs from the
Indian manufacturers Cipla and Matrix will give developing countries
leverage in bargaining with American companies for lower prices on branded
antiretroviral drugs and may embolden some to follow Brazil and Thailand in
overriding patents, AIDS activists said.



But developing countries still have reason to worry about retaliation from
drug companies and trade sanctions by the United States. This year, Abbott
Laboratories, based in Illinois, withdrew new drugs, including those for
high blood pressure

and AIDS, that it had planned to introduce in Thailand until the override
on Abbott’s patent on the second-line drug, Kaletra.



United States trade officials last week put Thailand on a watch list for
countries inadequately safeguarding the intellectual property rights of
American companies, noting the overriding of drug patents.



Tido von Shoen-Angerer, who leads the campaign by Doctors Without Borders
for access to medicines, said he was unsure whether the recent developments
would encourage developing countries to exercise their rights under
international trade rules more freely to make or import generic drugs.

“There’s a strong chilling effect from the U.S. action,” he said.



Drug company officials yesterday strongly defended their policies of
charging better-off developing countries more for AIDS drugs than they did
for poor countries, as well as the role of patents, which give inventor
companies a monopoly on the sale of a drug, in stimulating the development
of new drugs.



Jennifer Smoter, a spokeswoman for Abbott, said patents were needed “to
ensure innovation in the future” but declined to respond to Mr. Clinton’s
comment that “Abbott has been almost alone in its hard-line position here
over what I consider to be a life and death matter.”



Abbott had been charging $2,200 annually per patient for Kaletra in
middle-income developing countries, which include India, China, Brazil and
Ukraine. Last month, it dropped the price to $1,000. The foundation’s new
price for the generic is $695.



Jeffrey L. Sturchio, a vice president at Merck

in New Jersey, says his company strives to balance providing the broadest
possible access to AIDS drugs while maintaining financial incentives to
attract companies to conduct research and development on new drugs.



Brazil and Thailand have overridden Merck’s patent on the AIDS drug

The Clinton Foundation encouraged foreign companies to ignore (and break) US patent and intellectual property laws.

2016-09-20 Thread 'Perplexed' via PoliticalForum

And even the New York Times admitted it. I came across this in researching 
the recent allegations that the Clinton Foundation used an Indian drug 
manufacturer that is prohibited from selling drugs in the US due to its 
known horrific lack of quality. This was from 2007:

Clinton Foundation Announces a Bargain* on Generic AIDS Drugs 

By CELIA W. DUGGER MAY 9, 2007 

Former President Bill Clinton announced yesterday that his foundation had 
negotiated deep price reductions for generic versions of costly, 
second-line AIDS 

 
drugs needed when the original medicines fail, as well as for less toxic, 
easier-to-use first-line medicines combined in a pill that can be taken 
once a day.


Standing next to Thailand 
’s
 
health minister, Mr. Clinton also forcefully endorsed recent decisions by 
Thailand and Brazil 

 
to break patents held by American pharmaceutical companies that are 
charging prices Mr. Clinton described as exorbitant, but that drug company 
officials said were reasonable.

“No company will live or die because of high price premiums for AIDS drugs 
in middle-income countries, but patients may,” he said.


The new prices would halve the cost of the drugs for better-off developing 
countries in Latin America and Asia and cut prices by 25 percent in poor 
countries, which were already paying lower prices, the foundation said. The 
second-line medicines will be bought with more than $100 million raised by 
a group of countries led by France. The improved first-line therapies will 
largely be financed by the Global Fund to Fight AIDS, Tuberculosis and 
Malaria and other donors.


Second-line drugs have typically cost about 10 times as much as first-line 
therapies. Costs have ballooned in Brazil and Thailand, which began 
programs to provide universal access to AIDS treatment years before African 
countries did, as patients have developed resistance to generic first-line 
treatments and have moved to brand-name second-line drugs.


The Clinton Foundation’s willingness to buy the generic drugs from the 
Indian manufacturers Cipla and Matrix will give developing countries 
leverage in bargaining with American companies for lower prices on branded 
antiretroviral drugs and may embolden some to follow Brazil and Thailand in 
overriding patents, AIDS activists said.


But developing countries still have reason to worry about retaliation from 
drug companies and trade sanctions by the United States. This year, Abbott 
Laboratories, based in Illinois, withdrew new drugs, including those for 
high blood pressure 

 
and AIDS, that it had planned to introduce in Thailand until the override 
on Abbott’s patent on the second-line drug, Kaletra.


United States trade officials last week put Thailand on a watch list for 
countries inadequately safeguarding the intellectual property rights of 
American companies, noting the overriding of drug patents.


Tido von Shoen-Angerer, who leads the campaign by Doctors Without Borders 
for access to medicines, said he was unsure whether the recent developments 
would encourage developing countries to exercise their rights under 
international trade rules more freely to make or import generic drugs.

“There’s a strong chilling effect from the U.S. action,” he said.


Drug company officials yesterday strongly defended their policies of 
charging better-off developing countries more for AIDS drugs than they did 
for poor countries, as well as the role of patents, which give inventor 
companies a monopoly on the sale of a drug, in stimulating the development 
of new drugs.


Jennifer Smoter, a spokeswoman for Abbott, said patents were needed “to 
ensure innovation in the future” but declined to respond to Mr. Clinton’s 
comment that “Abbott has been almost alone in its hard-line position here 
over what I consider to be a life and death matter.”


Abbott had been charging $2,200 annually per patient for Kaletra in 
middle-income developing countries, which include India, China, Brazil and 
Ukraine. Last month, it dropped the price to $1,000. The foundation’s new 
price for the generic is $695.


Jeffrey L. Sturchio, a vice president at Merck 

 
in New Jersey, says his company strives to balance providing the broadest 
possible access to AIDS drugs while maintaining financial incentives to 
attract companies to conduct research and development on new drugs.


Brazil and Thailand have